Results 101 to 110 of about 72,546 (336)
Journal of Clinical and Biomedical Sciences, 2020 Giant cell tumor (GCT) account around 5% of bone tumors with a slight female preponderance. We are presenting a case 32yr old gentleman, who presented with c/o swelling present on lateral aspect of proximal third of left leg for past one year ...
Sakthikesavan sivanandan +3 more
doaj +1 more source
Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone [PDF]
, 2016 Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT.
Angelo Paolo Dei Tos +15 more
core +1 more source
Journal of Surgical Oncology, EarlyView.ABSTRACT Introduction The management of extremity soft tissue sarcomas (STS) involving major vessels presents unique challenges, historically leading to amputation. Advances in vascular reconstruction have enabled limb‐sparing surgery (LSS), but outcomes and perioperative risks remain uncertain.
Lucas Monteiro Delgado +9 more
wiley +1 more source
Giant-cell tumor of bone: treatment options and role of denosumab
Biologics: Targets & Therapy, 2015 Arun S Singh,1 Neal S Chawla,2 Sant P Chawla2 1Sarcoma Service, Division of Hematology/Oncology, University of California, Los Angeles, 2Sarcoma Oncology Center, Santa Monica, CA, USA Abstract: Giant-cell tumor of bone is a rare, locally aggressive ...
Singh AS, Chawla NS, Chawla SP
doaj
A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. [PDF]
, 2019 Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast ...
Chien, A Jo +5 more
core
Knee Surgery, Sports Traumatology, Arthroscopy, EarlyView.Abstract Purpose Extensor mechanism (EM) ruptures after total knee arthroplasty (TKA) are rare but lead to substantial functional impairment and morbidity. Treatment remains challenging due to the diversity of surgical techniques and the limited number of comparative studies.
Bruno Violante +12 more
wiley +1 more source
Giant cell tumor of soft tissue of hand: simple but rare diagnosis, which is often missed
Clinics and Practice, 2011 Giant cell tumor of soft tissue originally described in 1972 in two different series by Salm and Sissons is a rare entity, which is clinically and histopathologically indistinguishable from giant cell tumor of bone.
Sarwan Kumar, Lynn F. Carter
doaj +1 more source
Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab
Clinics in Orthopedic Surgery, 2019 Background Giant-cell tumor of bone (GCTB) is a locally aggressive primary benign tumor presenting as an expansile osteolytic lesion affecting the epiphysis of long bones.
P. Chinder +3 more
semanticscholar +1 more source
Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy
Medicine Bulletin, EarlyView.ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley +1 more source
Primary mediastinal giant cell tumor
Rare Tumors, 2009 Giant cell tumor of soft tissue is a rare tumor first described by Salm and Sissons in 1972 as being a distinct entity.1 Histologically, it is composed of multinucleated giant cells dispersed among mononuclear cells, and is indistinguishable from its ...
Jela Bandovic +3 more
doaj +1 more source